Skip to main content

Advertisement

SpringerLink
Log in

Cyclosporin a in rheumatoid arthritis: A critical review

  • Published:
InflammoPharmacology Aims and scope Submit manuscript

Abstract

Khawar K, Buchanan WW. Cyclosporin A in rheumatoid arthritis: a critical review. Inflammopharmacology. 1993;2:141–157. This paper reviews the current position of cyclosporin A in the therapeutic armamentarium of rheumatoid arthritis. The pharmacokinetic disposition, results of open and controlled trials, and toxicity will be reviewed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gilman SC, Lewis AJ. Immunodulatory drugs in the treatment of rheumatoid arthritis. In: Rainsford KD, ed. Anti-inflammatory and Anti-rheumatic Drugs, Vol. 3, Anti-rheumatic Drugs, Experimental Agents and Clinical Aspects of Drug Use. Boca Raton, FL: CRC Press; 1985:127–54.

    Google Scholar 

  2. Keown PA. Emerging indications for the use of cyclosporin in organ transplantations and autoimmunity. Drugs. 1990;40:315–25.

    PubMed  CAS  Google Scholar 

  3. Shand N, Richardson B. Sandimmun (cyclosporin A): mode of action and clinical results in rheumatoid arthritis. Scand J Rheumatol (suppl 76). 1988;17:265–78.

    Google Scholar 

  4. Harding MW, Handschumacher RE. Cyclosporin and its receptor, cyclophilin. In: Lewis A, Ackerman N, Otterness I eds. New Perspectives in Anti-inflammatory. Advances in Inflammation Research. New York: Raven Press; 1988; 12:283–94.

    Google Scholar 

  5. Borel JF. The history of cyclosporin A and its significance. In: White D, ed. Cyclosporin A. Amsterdam: Elsevier; 1982:5–17.

    Google Scholar 

  6. Handschumacher RE, Harding MW, Rice J et al. Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science. 1984;226:544–6.

    Article  PubMed  CAS  Google Scholar 

  7. Granelli-Piperno A, Andrus L, Steinman RM. Lymphokine and nonlymphokine in RNA levels in stimulated human T-cells: kinetics, mitogen requirements and effects of cyclosporin A. J Exp Med. 1986; 163:922–37.

    Article  PubMed  CAS  Google Scholar 

  8. Kahan BD. Cyclosporin. N Engl J Med. 1989;321:1725–37.

    Article  PubMed  CAS  Google Scholar 

  9. Kasaian MT, Biron CA. Cyclosporin A inhibition of interleukin 2 gene expression, but not natural killer cell proliferation, after interferon inducation in vivo. J Exp Med. 1990;171:745–62.

    Article  PubMed  CAS  Google Scholar 

  10. DeFranco AL. Immunosuppressants at work. Editorial. Nature. 1991;352:754–5.

    Article  PubMed  CAS  Google Scholar 

  11. White DJG, Calne RY. The use of cyclosporin A immunosuppression in organ grafting. Immunol Rev. 1982;65:115–31.

    Article  PubMed  CAS  Google Scholar 

  12. Borel JF. Immunosuppression: building on cyclosporin (Sandimmun). Transplant Proc. 1988;20(suppl l):149–53.

    PubMed  CAS  Google Scholar 

  13. Thomson AW, Nield GH. Cyclosporin use outside transplantation. Br Med J. 1991;302:4–5.

    CAS  Google Scholar 

  14. James DG. Cyclosporin. Br J Clin Pract. 1988;42:65–7.

    Google Scholar 

  15. Herman B, Muller W. Die Therapie der chronischen Polyarthritis mit Cyclosporin A, einen neuen Immunsuppressivum. Akt Rheumatol. 1979;4:173–86.

    Google Scholar 

  16. Graf U, Marbet U, Muller W et al. Cyclosporin A: effects and side-effects in the treatment of rheumatoid arthritis and psoriatic arthritis. Immun Inpekt. 1981;9:20–8.

    CAS  Google Scholar 

  17. Amor B, Dougados M. Cyclosporin in rheumatoid arthritis: open trials with different dosages. In: Schindler R, ed. Cyclosporin in Autoimmune Diseases. Berlin: Springer1985:283–7.

    Google Scholar 

  18. Bombardier C, Tugwell P, Gent M et al. A pilot study of CyA in patients with rheumatoid arthritis. In: Schindler R, ed. Cyclosporin in Autoimmune Diseases. Berlin: Springer. 1985:288.

    Google Scholar 

  19. Herog Ch, Gross D. Low dose cyclosporin A and prednisone: a step in the direction of selective immunosuppression in rheumatoid arthritis refractory of treatment (6-month follow-up). In: Schindler R, ed. Cyclosporin in Autoimmune Diseases. Berlin: Springer. 1985:289–96.

    Google Scholar 

  20. Madhok R, Capell HA. Cyclosporin in rheumatoid arthritis. In: Schindler R, ed. Cyclosporin in Autoimmune Diseases. Berlin: Springer. 1985:197–298.

    Google Scholar 

  21. Dougados M, Amor B. Cyclosporin A in rheumatoid arthritis: preliminary clinical results of an open trial. Arthritis Rheum. 1987;30:83–6.

    Article  PubMed  CAS  Google Scholar 

  22. Tugwell P, Bombardier C, Gent M et al. Low dose cyclosporin in rheumatoid arthritis: a pilot study. J Rheumatol. 1987;14:1108–14.

    PubMed  CAS  Google Scholar 

  23. Weinblatt ME, Coblyn JS, Fraser PA. Cyclosporin: a treatment of refractory rheumatoid arthritis. Arthritis Rheum. 1987;30:ll-7.

    Article  Google Scholar 

  24. Dougados M, Awada H, Amor B. Cyclosporin in rheumatoid arthritis: a double blind, placebo controlled study in 52 patients. Ann Rheum Dis. 1988;47:127–33.

    PubMed  CAS  Google Scholar 

  25. Yocum DE, Klippel JH, Wilder RL et al Cyclosporin A in severe, treatment-refractory rheumatoid arthritis. A randomized study. Ann Intern Med. 1988;863-9.

  26. Dougados M, Duchesne L, Awada H, Amor B. Assessment of efficacy and acceptability of low dose cyclosporin in patients with rheumatoid arthritis. Ann Rheum Dis. 1989;48:550–6.

    PubMed  CAS  Google Scholar 

  27. Tugwell P, Bombardier C, Gent M et al. Low dose cyclosporin versus placebo in patients with rheumatoid arthritis. Lancet. 1990;335:10Sl-5.

    Article  Google Scholar 

  28. Borel JF, Feuer C, Gubler HU, Stahelin H. Biological effects of cyclosporin A: a new antilymphocyte agent. Agents Actions. 1976;6:468–75.

    Article  PubMed  CAS  Google Scholar 

  29. Yocum DE, Allen JB, Wahl SM et al. Inhibition by cyclosporin A of streptococcal cell wall-induced arthritis and hepatic granulomas in rats. Arthritis Rheum. 1986;29:262–74.

    Article  PubMed  CAS  Google Scholar 

  30. Bersani-Amado CA, Duarte AJ daS, Tanji MM et al. Comparative study of adjuvant induced arthritis in susceptible and resistant strains of rats. III. Analysis of lymphocyte subpopulations. J Rheumatol. 1990;17:153–8.

    CAS  Google Scholar 

  31. Cannon W, McCall S, Cole BC et al. Effects of indomethacin, cyclosporin, cyclophosphamide, and placebo on collagen-induced arthritis of mice. Agents Actions. 1990;29:315–23.

    Article  PubMed  CAS  Google Scholar 

  32. Del Pozo E, Graeber M, Elford P, Payne T. Regression of bone and cartilage loss in adjuvant arthritis rats after treatment with cyclosporin A. Arthritis Rheum. 1990;33:247–52.

    Article  PubMed  Google Scholar 

  33. Drewe J, Beglinger C, Kissel T. The absorption site of cyclosporin in the human gastrointestinal tract. Br J Clin Pharmacol. 1992;33:39–43.

    PubMed  CAS  Google Scholar 

  34. Tachinski RJ, Venkataramanan R, Burekart GJ. Because of its lipophilic nature CyA’s absorption is facilitated by bile. Clinical pharmacokinetics of cyclosporin. Clin Pharmacokinet. 1986;ll:107–32.

    Google Scholar 

  35. Borel JF. The cyclosporins. Transplant Proc. 1989;21:810–5.

    PubMed  CAS  Google Scholar 

  36. Schwinghammer TL, Przepiorka D, Venkataramanan R et al. The kinetics of cyclosporine and its metabolites in bone marrow transplant patients. Br J Clin Pharmac. 1991;32:323–8.

    CAS  Google Scholar 

  37. Tjia JF, Webber IR, Back DJ. Cyclosporin metabolism by the gastrointestinal mucosa. Br J Clin Pharmacol. 1991;31:344–6.

    PubMed  CAS  Google Scholar 

  38. Kolars JC, Awnni WM, Merion RM et al. First-pass metabolism of cyclosporin by the gut. Lancet. 1991;338:1488–90.

    Article  PubMed  CAS  Google Scholar 

  39. Lucey MR, Kolars JC, Merion RM et al. Cyclosporin toxicity at therapeutic blood levels and cytochrome P-50 IIIA. Lancet. 1990;335:ll-5.

    Article  Google Scholar 

  40. Herricsson S. A sulfate conjugate of cyclosporin. Pharmacol Toxicol. 1990;66:53–5.

    Google Scholar 

  41. Habucky K, Venkataramanan R, Ptacheinski RJ et al. Pharmacokinetics of cyclosporine after single and chronic administration in male beagle dogs. Pharm Res. 1990;7(suppl):265–76.

    Google Scholar 

  42. Augustine JA, Zemaitis MA. The effects of cyclosporine A (CyA) on hepatic microsomal drug metabolism in the rat. Drug Metab Dispos. 1986;14:73–8.

    PubMed  CAS  Google Scholar 

  43. Venkataramanan R, Starzi YE, Yang S et al. Biliary excretion of cyclosporin in liver transplant patients. Transplant Proc. 1985; 17:286–9.

    Google Scholar 

  44. Maurer G, Lemaire M. Biotransformation and distribution in blood of cyclosporin and its metabolites. Transplant Proc. 1986;18(suppl 5):25–34.

    PubMed  CAS  Google Scholar 

  45. Lemaire M, Tillement JP. Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood. J Pharm Pharmacol. 1982;34:715–8.

    PubMed  CAS  Google Scholar 

  46. Akagi H, Reynolds A, Hjelm M. Cyclosporin A and its metabolites, distribution in blood and tissues. J Int Med Res. 1991;19:1–18.

    PubMed  CAS  Google Scholar 

  47. Task Force on Cyclosporin Monitoring. Critical issues in cyclosporin monitoring: report of the task force on cyclosporin monitoring. Clin Chem. 1987;33:1269–88.

    Google Scholar 

  48. Christians U, Schlitt HJ, Bleck JS et al. Measurement of cyclosporin and 18 metabolites in blood, bile and urine by high-performance liquid chromatography. Transplant Proc. 1988;20(suppl 2):609–13.

    PubMed  CAS  Google Scholar 

  49. Dusci LJ, Hackett LP, Chiswell GM, Ilett KF. Comparison of cyclosporine measurement in whole blood by high performance liquid chromatography, monoclonal fluorescence polerization immunoassay, and monoclonal enzyme-multiplied immunoassay. Ther Drug Monit. 1992;14:327–32.

    Article  PubMed  CAS  Google Scholar 

  50. Consensus Document: Hawk’s Bay meeting on therapeutic drug monitoring of cyclosporin. Clin Chem 1990;36:1510-6.

    Google Scholar 

  51. Donatsch P, Abish E, Hornberger M et al. A radioimmunoassay to measure cyclosporin in plasma and serum samples. J Immunoassay. 1982;2:19–32.

    Google Scholar 

  52. Kahan BD, Grevel J. Optimization of cyclosporin therapy in renal transplantation by a pharmacokinetic strategy. Transplantation. 1988;46:631–44.

    Article  PubMed  CAS  Google Scholar 

  53. Van Rijthoven AWAM, Dijkmans BAC, Goei The HS et al. Penetration of cyclosporin into synovial fluid in rheumatoid arthritis. Eur J Clin Pharmacol. 1989;37:321–2.

    Article  PubMed  Google Scholar 

  54. Forre O, Bjerkhoel F, Salvesem CF et al. An open, controlled, randomized comparison of cyclosporin and azathioprine in the treatment of rheumatoid arthritis: a preliminary report. Arthritis Rheum. 1987;30:88–92.

    Article  PubMed  CAS  Google Scholar 

  55. Capone M, Saber S, Musculo V, Capone A. Cyclosporine A in therapy refractory rheumatoid arthritis. Br J Rheumatol. 1992;31(suppl 2):130A.

    Google Scholar 

  56. Madhok R, Torley HI, Capell HA. A study of the long term efficacy and toxicity of cyclosporine A in rheumatoid arthritis. J Rheumatol. 1991;18:1485–9.

    PubMed  CAS  Google Scholar 

  57. Van Rijthoven AWAM, Dijkmans BAC, Goei The HS et al. Long term cyclosporine therapy in rheumatoid arthritis. J Rheumatol. 1991;18:19–23.

    PubMed  Google Scholar 

  58. Van Rijthoven AWAM, Dijkmans BAC, Goei Thè HSG et al. Cyclosporin treatment for rheumatoid arthritis: a placebo controlled, double-blind, multicentre study. Ann Rheum Dis. 1986;45:726–31.

    PubMed  Google Scholar 

  59. Van Rijthoven AWAM, Dijkmans BAC, Goei Thè HS et al. Comparison of cyclosporine and D-penicillamine for rheumatoid arthritis. A randomized, double-blind, multicentre study. J Rheumatol. 1991;18:815–20.

    PubMed  Google Scholar 

  60. Ahern MJ, Harrison W, Hollingworth P et al. A randomized, double-blind trial of cyclosporin and azathioprine in refractory rheumatoid arthritis. Aust NZ J Med. 1991;21:844–9.

    CAS  Google Scholar 

  61. Kruger K, Schattenkirchner M, Petersen AK, Shand N. Long-term treatment of rheumatoid arthritis with cyclosporin A. Br J Rheumatol. 1992;31(suppl 2):128A.

    Google Scholar 

  62. Ritchie DM, Boyle J, Mclnnes J et al. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med. 1968;37:393–406.

    PubMed  CAS  Google Scholar 

  63. Lee P, Jasani MK, Dick WC, Buchanan W. Evaluation of a functional index in rheumatoid arthritis. Scand J Rheumatol. 1973;2:71–7.

    PubMed  CAS  Google Scholar 

  64. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc. 1949;140:659–62.

    PubMed  CAS  Google Scholar 

  65. Max MB, Schafer SC, Culnane M et al. Association of pain relief with drug side-effects in post hepatic neuralgia. Clin Pharmacol Ther. 1988;43:363–71.

    Article  PubMed  CAS  Google Scholar 

  66. Huskisson EC, Scott J. How double-blind is double-blind? And does it matter? Br J Clin Pharmacol.. 1976;3:331–2.

    PubMed  CAS  Google Scholar 

  67. Palestine AR, Nussenblatt RB, Chan CC. Side-effects of systemic cyclosporin in patients not undergoing transplantation. Am J Med. 1984;77:652–6.

    Article  PubMed  CAS  Google Scholar 

  68. Dijkmans BAC, Van Rijthoven AWAM, Goei The HS et al. Cyclosporin in rheumatoid arthritis. Semin Arthritis Rheum. 1992;22:30–6.

    Article  PubMed  CAS  Google Scholar 

  69. Hoffin JM, Potasman I, Baldwin JC et al. Infectious complications in heart transplant recipients receiving cyclosporin and corticosteroids. Ann Intern Med. 1987;106:209–16.

    Google Scholar 

  70. Dawson T, Ryan PFJ, Findeisen JM, Scheinkestel CD. Pneumocystis carinii pneumonia following cyclosporin A and methotrexate treated rheumatoid arthritis. J Rheumatol. 1992;19:997.

    PubMed  CAS  Google Scholar 

  71. Pillemer SR, Webb D, Yocum DE. Legionnaire’s disease in a patient with rheumatoid arthritis treated with cyclosporin. J Rheumatol. 1989;16:117–20.

    PubMed  CAS  Google Scholar 

  72. Foley RN, Barrett BJ, Parfrey PS. Toxic nephropathy. Ann RCPSC. 1992;25:46–50.

    Google Scholar 

  73. Buchanan WW. Cyclosporin: clinical efficacy and toxicity in patients with rheumatoid arthritis. In Rainsford KD, Velo GP, eds. Side-effects of anti-inflammatory drugs 3, Inflammation and drug therapy series Vol. 5. Lancaster: Kluwer Academic Publishers; 1992:302–10.

    Google Scholar 

  74. Mihatsch MJ, Oliviere W, Marbet U et al. Giant mitochondria in renal tubular cells and cyclosporin A. Lancet. 1981;l:1162–3.

    Article  Google Scholar 

  75. Jung K, Pergande M. Influence of cyclosporin A on the respiration of rat kidney mitochondria. FEBS Lett. 1985;183:167–9.

    Article  PubMed  CAS  Google Scholar 

  76. Stahl RAK, Kudelka S. Chronic cyclosporin A treatment reduces prostaglandin E-2 formation in isolated glomeruli and papilla of rat kidney. Clin Nephrol. 1986;25(suppl l):78–82.

    Google Scholar 

  77. Jung K, Reinholdt C, Scholz P. Inhibitory efficiency of the kidney mitochondria from rats treated with cyclosporin A. Nephron. 1987;45:43–5.

    Article  PubMed  CAS  Google Scholar 

  78. Crompton M, Ellinger H, Costi A. Inhibition of cyclosporin A of a Ca2+ -dependent pore in heart mitochondria activated by inorganic phosphate and oxidative stress. Biochem J. 1988;255:357–60.

    PubMed  CAS  Google Scholar 

  79. Broekemeier KM, Dempsey ME, Preiffer DK. Cyclosporin A is a potent inhibitor of the inner membrane permeability transition in liver mitochondria. J Biol Chem. 1989;264:7826–30.

    PubMed  CAS  Google Scholar 

  80. Erman A, Chen-Gal B, Rosenfeld J. Cyclosporin treatment alters prostanoid and thromboxane production by rat isolated kidney mitochondria. J Pharm Pharmacol. 1990;42:181–5.

    PubMed  CAS  Google Scholar 

  81. Kopp JB, Klotman PE. Cellular and molecular mechanisms of cyclosporin nephrotoxicity. J Am Soc Nephrol. 1990;l:162–79.

    Google Scholar 

  82. Kahan BD. Cyclosporin nephrotoxicity: pathogenesis, prophylaxis, therapy and prognosis. Am J Kid Dis. 1986;8:323–31.

    PubMed  CAS  Google Scholar 

  83. Branthwaite JP, Nicholls A. Cyclosporin and diclofenac interaction in rheumatoid arthritis. Lancet. 1991;337:252.

    Article  PubMed  CAS  Google Scholar 

  84. Whiting PH, Barnard N, Neilsch A et al. Interactions between cyclosporin A, indomethacin and 16,16-di-methyl prostaglandin E ; Effects on renal, hepatic and gastrointestinal toxicity in the rat. Br J Exp Pathol. 1987;68:777–86.

    PubMed  CAS  Google Scholar 

  85. Berg KJ, Forre O, Djoseland O, Mikkelsen M et al. Renal side-effects of high and low cyclosporin A doses in patients with rheumatoid arthritis. Clin Nephrol. 1989;31:232–8.

    PubMed  CAS  Google Scholar 

  86. Berg KJ, Forre O, Bjerkhoel F et al. Side-effects of cyclosporin A treatment in patients with rheumatoid arthritis. Kidney Int. 1986;29:1180–7.

    Article  PubMed  CAS  Google Scholar 

  87. Dijkmans BAC, Van Rijthoven AWAM, Goei Thè HS et al. Effect of cyclosporin on serum creatinine in patients with rheumatoid arthritis. Eur J Clin Pharmacol. 1987;31:541–5.

    Article  PubMed  CAS  Google Scholar 

  88. Boers M, Dijkmans BAC, Van Rijthoven AWAM et al. Reversible nephrotoxicity of cyclosporine in rheumatoid arthritis. J Rheumatol. 1990;17:38–42.

    PubMed  CAS  Google Scholar 

  89. Deray G, Benhmida M, Le Hoang P, Maksud P et al. Renal function and blood pressure in patients receiving long term, low dose cyclosporine therapy for idiopathic autoimmune uveitis. Ann Int Med. 1992;117:578–83.

    PubMed  CAS  Google Scholar 

  90. Palier M. The prostaglandin E-l analog misoprostol reverses acute cyclosporin nephrotoxicity. Transplant Proc. 1988;20(suppI 3):634–7.

    Google Scholar 

  91. Moran M, Mozes M, Maddux MS et al. Prevention of acute graft rejection by the prostaglandin E analogue, misoprostol in renal transplant recipients treated with cyclosporine and prednisone. N Engl J Med. 1990;322:1183–8.

    Article  PubMed  CAS  Google Scholar 

  92. Boers M, Bensen WG, Ludwin D et al. Cyclosporine nephrotoxicity in rheumatoid arthritis: No effect of short term misoprostol treatment. J Rheumatol. 1992; 19:534–7.

    PubMed  CAS  Google Scholar 

  93. Elzinga L, Kelley VE, Houghton DC et al. Modification of experimental nephrotoxicity with fish oil as the vehicle for cyclosporin transplantation. Transplantation. 1987;43:271–4.

    Article  PubMed  CAS  Google Scholar 

  94. Bianco J, Alugren J, Kern D et al. Evidence that oral pentoxifylline reverses acute renal dysfunction in bone marrow transplant recipients, receiving amphoterecin B and cyclosporine A. Transplantation. 1991;51:925–7.

    Article  PubMed  CAS  Google Scholar 

  95. Brunner LJ, Vadiei K, Lyer LV, Luke DR. Prevention of cyclosporine-induced nephrotoxicity with pentoxifylline. Renal Failure. 1989;ll:97–104.

    Google Scholar 

  96. Buchanan WW, Brooks PM. Prediction of organ system toxicity with anti-rheumatic disease therapy. In: Bellamy N, ed. Prognosis of the Rheumatic Diseases. Dordrecht: Kluwer.. 1991:403–90.

    Google Scholar 

  97. Ludwin D, Bennett KJ, Grace EM et al. Nephrotoxicity in patients with rheumatoid arthritis treated with cyclosporine. Transplant Proc. 1988;20(suppl 4):367–70.

    PubMed  CAS  Google Scholar 

  98. von Graffenried B, Harrison WB. Renal function in patients with autoimmune diseases treated with cyclosporin. Transplant Proc. 1985;17(suppl 1):215.

    Google Scholar 

  99. Cohen DJ, Appel GB. Cyclosporine: Nephrotoxic effects and guidelines for safe use in patients with rheumatoid arthritis. Semin Arthritis Rheum. 1992;21(suppl 3):43–8.

    Article  PubMed  CAS  Google Scholar 

  100. FentrenG, Mihatsh MJ. Risk factors for cyclosporine induced nephropathy in patients with autoimmune diseases. N Engl J Med. 1992;326:1654–60.

    Article  Google Scholar 

  101. Pincus T, Callahan LF. Reassessment of twelve traditional paradigms concerning the diagnosis, prevalence, morbidity and mortality of rheumatoid arthritis. Scand J Rheumatol 1989;(S79):67–95.

  102. Hannedouche TP, Delago AG, Gnionsahe AD et al. Nephrotoxicity of cyclosporine in autoimmune diseases. Adv Nephrol. 1990; 19:169–86.

    CAS  Google Scholar 

  103. Hakulinen T, Isomaki H, Knekt P. Rheumatoid arthritis and cancer studies based on linking nationwide registries in Finland. Am J Med. 1985;78(suppl lA):29–32.

    Article  PubMed  CAS  Google Scholar 

  104. Cockburn ITR, Krupp P. The risk of neoplasms in patients treated with cyclosporin A. J Autoimmunity. 1989;2:723–31.

    Article  CAS  Google Scholar 

  105. Ziylmans JMJM, Van Rijthoven AWAM, Kluin PM et al. Epstein-Barr virus-associated lymphoma in a patient with rheumatoid arthritis treated with cyclosporine. N Engl J Med. 1992;326:1363.

    Google Scholar 

  106. Khawar K, Buchanan WW. A case of pseudo-lymphoma in a cyclosporin treated rheumatoid arthritis patient, [in press].

  107. Drosos AA, Skopouli FN, Costopoulos JS et al. Cyclosporin A (CyA) in primary Sjogren’s syndrome: a double-blind study. Ann Rheum Dis. 1986;45:732–5.

    PubMed  CAS  Google Scholar 

  108. MacLeod AM, Thomson AW. FK506: an immunosuppressant for the 1990’s? Lancet. 1991:337:25–7.

    Article  PubMed  CAS  Google Scholar 

  109. Brooks PM, Schwarzer AC. Combination chemotherapy in rheumatoid arthritis. Ann Rheum Dis. 1991;50:507–9.

    PubMed  CAS  Google Scholar 

  110. Lavalle C. Prolactin - A hormone with immunoregulatory properties. Editorial. R Rheumatol. 1992;19:839–41.

    CAS  Google Scholar 

  111. Denman AM. Novel treatment for rheumatoid arthritis. Editorial. Br J Rheumatol. 1992;31:577–81.

    Article  PubMed  CAS  Google Scholar 

  112. Bunjes D. Cyclosporin A - An immunosuppressive drug specific for T-helper cells. Triangle. 1983;22:181–7.

    Google Scholar 

  113. Skjodt H, Crawford A, Elford PR et al. Cyclosporin A modulates interleukin-1 activity on bone in vitro. Br J Rheumatol. 1985;24:165–9.

    Google Scholar 

  114. Russell G, Graveley R, Janet S et al. Mechanisms of action of cyclosporine and effects on connective tissues. Semin Arthritis Rheumat. 1992;21:16–22.

    Article  CAS  Google Scholar 

  115. Lindholm A, Welsh M, Alton C, Kahan BD. Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: Racial differences in bioavailability. Clin Pharmacol Ther. 1992;52:359–71.

    Article  PubMed  CAS  Google Scholar 

  116. Gupta SK, Manfro RC, Tamlanovich SJ et al. Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration. J Clin Pharmacol. 1990;30:643–53.

    PubMed  CAS  Google Scholar 

  117. Gupta SK, Barkam A, Johnson RWG, Rowland M. Cyclosporin-erythromycin interaction in renal transplant patients. Br J Clin Pharmac. 1989;27:475–81.

    CAS  Google Scholar 

  118. Gerson B. Cyclosporine controversies. Ther Drug Monit. 1987;7:669–88.

    CAS  Google Scholar 

  119. Prichard L, Fabre I, Fabre G et al. Cyclosporin A, drug interactions: Screening for inducers and inhibitors of cytochrome P-450 (cyclosporine A oxidase) in primary cultures of human hepatocytes, in liver microsomes. Drug Metab Dispos. 1990;18:595–606.

    Google Scholar 

  120. Landewe RBM, Miltenburg AMM, Breedveld FC et al. Cyclosporine and chloroquine synergistically inhibit interferon-gamma-production by CD4 positive and CD8 positive synovial T-cell clones derived from a patient with rheumatoid arthritis. J Rheumatol. 1992; 19:1353–7.

    PubMed  CAS  Google Scholar 

  121. Forman SJ, Textor SC, Carlson JE. Prednisone potentiates cyclosporine-induced blood pressure changes in normotensive bone-marrow transplant recipients. Kidney Int. 1987;31:297A.

    Google Scholar 

  122. Watkins PB, Wrighton SA, Schultz EG et al. Identification of glucocorticoid-inducible cytochrome P-450 in the intestinal mucosa of rats and man. J Clin Invest. 1987;80:129–36.

    Google Scholar 

  123. Whiting PH, Burke MD, Thompson AW. Drug interactions with cyclosporine. Implications from animal studies. Transplant Proc. 1986;18(suppl 5):56–70.

    PubMed  CAS  Google Scholar 

  124. Whiting PH, Cunningham C, Thompson AW, Simpson JG. Enhancement of high dose cyclosporin A toxicity with frusemide. Biochem Pharm. 1984;33:1075–9.

    Article  PubMed  CAS  Google Scholar 

  125. Holt DW, Johnston A. Cyclosporin and vitamin E. Lancet. 1991;338:697.

    Article  PubMed  CAS  Google Scholar 

  126. Powless AV, Baker BS, Fry L, Valdimarsson H. Cyclosporin toxicity. Lancet. 1990;335:610.

    Article  Google Scholar 

  127. Hebert MF, Roberts JP, Prueksaritanont P, Benet LZ. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther. 1992;52:453–7.

    Article  PubMed  CAS  Google Scholar 

  128. Rowland M, Gupta SK. Cyclosporin-phenytoin interaction: re-evaluation using metabolic data. Br J Clin Pharmacol. 1987;24:329–34.

    PubMed  CAS  Google Scholar 

  129. Prichar DL, Gillet G, Fabre I et al. Identification of the rabbit and human cytochromes P-450 III A as the major enzymes involved in the N-demethylation of diltiazem. Drug Metab Dispos. 1990;18:711–9.

    Google Scholar 

  130. Kronbach T, Mathys D, Umeno M et al. Oxidation of midazolam and triazolam by human cytochrome P-450 III A4. Mol Pharmacol. 1989;36:89–96.

    PubMed  CAS  Google Scholar 

  131. McNally P, Mistry N, Idle J et al. Calcium channel-blockers and cyclosporine metabolism. Transplantation. 1989;48:1071.

    Article  PubMed  CAS  Google Scholar 

  132. Deray G, Le Hoang P, Cacoub P et al. Oral contraceptive interaction with cyclosporin. Lancet. 1987;?:158-9.

    Google Scholar 

  133. Boissier MC, Chiocchia G, Fournier C. Combination of cyclosporine A and calcitriol in the treatment of adjuvant arthritis. J Rheumatol. 1992;19:754–7.

    PubMed  CAS  Google Scholar 

  134. Nagineni CN, Misra BC, Lee BDN et al. Cyclosporine A - a calcium channels interaction: a possible mechanism for nephrotoxicity. Transplant Proc. 1987;19:1358–62.

    PubMed  CAS  Google Scholar 

  135. Wagner K, Henkel M, Heinemeyer G et al. Interaction of calcium blockers and cyclosporine. Transplant Proc. 1988;20(suppl 2):561–8.

    PubMed  CAS  Google Scholar 

  136. Dadar J, Perico N, Remuzzi G. Role of endothelin in cyclosporine-induced renal vasoconstriction. Kidney Int. 1990;37:291A.

    Google Scholar 

  137. Remuzzi G, Bertani T. Renal vascular and thrombotic effects of cyclosporine. Am J Kidney Dis.1989;13:261–72.

    PubMed  CAS  Google Scholar 

  138. Dieperin Kh, Leyssac PP, Kemp E et al. Nephrotoxicity of cyclosporin A in humans: Effects of glomerular filtration and tubular reabsorption rate. Eur J Clin Invest. 1987;17:493.

    Article  Google Scholar 

  139. Voss BL, Hamilton KK, Samara ENS et al. Cyclosporine suppression of endothelial prostacycline generation. Transplantation. 1988;45:793–6

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Rheumatology, Section of Medicine, McMaster University Faculty of Health Sciences, 1200 Main Street, L8N 3Z5, Hamilton, Ontario, Canada

    K. Khawar, K. Al-jarallah & W. W. Buchanan

Authors
  1. K. Khawar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Al-jarallah
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W. W. Buchanan
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Khawar, K., Al-jarallah, K. & Buchanan, W.W. Cyclosporin a in rheumatoid arthritis: A critical review. Inflammopharmacology 2, 141–157 (1993). https://doi.org/10.1007/BF02659091

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02659091

Keywords

Search

Navigation